MCCA
RXST icon

Mill Creek Capital Advisors’s RxSight RXST Stock Holding History

Mill Creek Capital Advisors’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,877
Closed -$252K – 254
2022
Q4 		$252K Buy
+19,877
New +$242K 0.01% 195

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Mill Creek Capital Advisors's RXST Position: Q1 2023 in Review

Mill Creek Capital Advisors sold out of RxSight (RXST) in Q1 2023, closing a stake of 19,877 shares — an estimated $252K sold.

Mill Creek Capital Advisors first reported a position in RXST in Q4 2022 and held it in 1 quarter. The position peaked at $252K in Q4 2022. 74 funds tracked by Wall St. Rank hold RXST as of Q1 2023.

  • Mill Creek Capital Advisors reported no remaining RxSight position as of Q1 2023 after selling out during the quarter.
  • Mill Creek Capital Advisors sold 19,877 RxSight shares in Q1 2023, an estimated $252K.
  • Mill Creek Capital Advisors first reported a position in RxSight in Q4 2022 and held it in 1 quarter.
  • Mill Creek Capital Advisors's RxSight position peaked at $252K in Q4 2022.
  • 74 funds tracked by Wall St. Rank held RxSight as of Q1 2023.

Based on Mill Creek Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.